Search
Log in
Sign up
Watch fullscreen
Eli Lilly Nears First Trillion Pharma Title, But Investors Caution Amid Sky-High Valuation
Benzinga
Follow
Like
Bookmark
Share
Add to Playlist
Report
2 months ago
Eli Lilly's valuation stands at $842 billion, 54x projected earnings. Orforglipron could be the first small-molecule weight-loss pill when it launches in 2026, giving Eli Lilly two-year lead before rivals catch
Category
🗞
News
Show less
Recommended
3:45
I
Up next
Full Video: Trump's Christmas Message To The U.S Ahead of Oath Taking Ceremony
Oneindia
3:34
Blast at Alania Mall in Russia Kills One, Injures Two; Fire Affects 800 sqm, Contained in an Hour
Oneindia
1:04
Jim Cramer Sees Eli Lilly As More Than A 'One-Trick Pony' After FDA Advisors Back Its Alzheimer's Drug: 'It's Ultimately Headed To A Trillion Dollar Valuation'
Benzinga
4:16
Piper's Sandler's Craig Johnson Puts $6,600 Target On $SPX For 2025
Benzinga
1:00
Demand Soars For Novo Nordisk's Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly Competition
Benzinga
4:15
Something Is Happening In The Utilities Sector That Investors Should Watch Out For | $XLU
Benzinga
4:17
Apple Stock Dips After KeyBanc Cuts Rating On iPhone Sale Concerns: What Investors Need To Know
Benzinga
0:58
Charlie Munger Revealed What Was Left On His Bucket List Before He Died
Benzinga
6:39
What turns around the value stocks?
Benzinga
1:12
Warren Buffett's Berkshire Hathaway, Elon Musk's Tesla And Eli Lilly Could Be Next Trillion-Dollar Companies After Nvidia's Rapid Ascension: Jim Cramer
Benzinga
2:45
Can The S&P 500 Reach $6000 Before Year End? | Jay Woods, CMT, Chief Global Strategist, Freedom Markets
Benzinga
1:00
Billionaire Bill Ackman's Hedge Fund Pershing Square To Go Public At $50 Per Share
Benzinga
3:04
How End Of Month Buy And Sell Imbalances Effected Stock Movements
Benzinga
0:37
Eli Lilly's Mounjaro Outpaces Novo Nordisk's Ozempic In Weight Loss Effectiveness, Study Shows
Benzinga
13:34
"The Second Half Of September Is When The Trouble Tends To Come" - Ryan Detrick, CMT, Carson Group
Benzinga
1:11
Microsoft Races To The Top, Hits $3-Trillion Valuation, Challenges Apple's Throne
Benzinga
4:07
Nike Q1 Earnings Highlights: EPS Beats As North American Sales Slide, Shares Move Higher
Benzinga
4:01
Is Japan The Right Country To Invest In Right Now? - Jeremy Schwartz, Global Chief Investment Officer @WisdomTreeFunds
Benzinga
1:40
Is Managing Volatility Really An Asset Class?
Benzinga
1:31
Why Is The Fed Still So Aggressive? - Jeremy Schwartz, Chief Investment Officer at WisdomTree
Benzinga
0:46
Zscaler Q1 Earnings: Revenue Beat, EPS Beat, New AI Opportunities, Shares Slide
Benzinga
17:00
Volatility And Momentum In The Market - Cameron Dawson, CIO NewEdge Wealth
Benzinga
0:52
Lululemon Q3 Earnings: Revenue Beat, EPS Beat, $1B Buyback Increase, 'Continued Momentum' Across International Markets
Benzinga
5:17
Housing stocks Not As Quiet As People Think - $TPH $BZH $PHM
Benzinga
4:12
No Bid For Defensives and What Are The Bond Markets Telling Us? - Cameron Dawson, CFA, Chief Investment Officer, NewEdge Wealth
Benzinga